[
  {
    "objectID": "quarto/main.html",
    "href": "quarto/main.html",
    "title": "The Financial Toxicity of Universal SGLT2i in HF",
    "section": "",
    "text": "— CONSORT FLOW DIAGRAM DATA (Person-Years) —\nSTEP 1: Total MEPS Population (2021-2023) | N = 69,686\nExclusion 1: No HF Diagnosis | n = 69,141\nSTEP 2: Heart Failure Diagnosis (CCSR: CIR019) | N = 545 (0.8%)\nExclusion 2: Pediatric &lt; 18 | n = 0 (0.0%)\nSTEP 3: Adult Population (Age &gt;= 18) | N = 545 (100.0%)\nExclusion 3: No GDMT Exclusion (Universal Sample Retained) | n = 0\nSTEP 4: Broad HF Cohort | N = 545 (100.0%)\nExclusion 4: Uninsured/Other | n = 12 (2.2%)\nSTEP 5: Final Analytic Cohort (Valid Insurance) | N = 533 (97.8%)\n\n\n\n\n\n\n\nTable 1. Weighted Baseline Demographic and Clinical Characteristics of the U.S. HF Population (2021–2023).\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\nCharacteristic\nOverall N = 1,833,138 (100%)1\nCommercial N = 167,779 (9.2%)1\nMedicaid/Dual N = 582,020 (32%)1\nMedicare N = 1,083,339 (59%)1\n\n\n\n\nAge Category\n\n\n\n\n\n\n\n\n\n\n    &lt;65\n610,131 (33%)\n167,779 (100%)\n367,772 (63%)\n74,580 (6.9%)\n\n\n    65-74\n421,899 (23%)\n0 (0%)\n117,246 (20%)\n304,653 (28%)\n\n\n    75+\n801,109 (44%)\n0 (0%)\n97,003 (17%)\n704,106 (65%)\n\n\nSex\n\n\n\n\n\n\n\n\n\n\n    Male\n840,041 (46%)\n110,333 (66%)\n222,755 (38%)\n506,953 (47%)\n\n\n    Female\n993,097 (54%)\n57,446 (34%)\n359,266 (62%)\n576,386 (53%)\n\n\nRace/Ethnicity\n\n\n\n\n\n\n\n\n\n\n    White\n1,336,511 (73%)\n89,572 (53%)\n353,994 (61%)\n892,945 (82%)\n\n\n    Asian/Other\n95,747 (5.2%)\n20,738 (12%)\n46,213 (7.9%)\n28,797 (2.7%)\n\n\n    Black\n310,743 (17%)\n57,469 (34%)\n132,585 (23%)\n120,688 (11%)\n\n\n    Hispanic\n90,137 (4.9%)\n0 (0%)\n49,229 (8.5%)\n40,909 (3.8%)\n\n\nIncome Tier\n\n\n\n\n\n\n\n\n\n\n    Low\n780,289 (43%)\n25,239 (15%)\n396,151 (68%)\n358,899 (33%)\n\n\n    Mid\n541,851 (30%)\n69,908 (42%)\n120,024 (21%)\n351,918 (32%)\n\n\n    High\n510,999 (28%)\n72,632 (43%)\n65,845 (11%)\n372,522 (34%)\n\n\nCurrent SGLT2i Use\n242,314 (13%)\n32,709 (19%)\n72,502 (12%)\n137,103 (13%)\n\n\nTotal Prescription OOP ($)\n187 (38, 542)\n188 (90, 332)\n32 (3, 112)\n351 (148, 899)\n\n\nTotal Medical OOP ($)\n694 (143, 2,481)\n1,072 (575, 2,890)\n121 (27, 422)\n1,406 (421, 3,494)\n\n\n\n1 n (%); Median (Q1, Q3)\n\n\nNotes: Data derived from the Medical Expenditure Panel Survey (MEPS), pooled 2021–2023. Values represent weighted national estimates.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 2. Projected Incidence of Financial Toxicity Among Medicare Beneficiaries Under Universal SGLT2i vs. The Inflation Reduction Act.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (%)\nRelative Reduction (%)\n\n\n\n\nOverall Population\n\n\nAll Medicare Beneficiaries\n26.2 (19.7-33.6)\n30.5 (23.3-38.6)\n29.3 (21.9-37.5)\n1.3\n4.2\n\n\nAge Group\n\n\n&lt;65\n26.6 (NC)\n42.4 (NC)\n42.4 (NC)\n0.0\n0.0\n\n\n65-74\n26.4 (13.5-43.3)\n31.1 (17.2-48.1)\n30.6 (16.6-47.8)\n0.6\n1.8\n\n\n75+\n26.1 (17.7-36.0)\n29.0 (20.1-39.4)\n27.3 (18.4-37.7)\n1.7\n6.0\n\n\nSex\n\n\nMale\n23.8 (14.6-35.2)\n30.6 (19.4-43.8)\n27.9 (16.4-41.9)\n2.8\n9.0\n\n\nFemale\n28.4 (19.1-39.2)\n30.5 (20.8-41.6)\n30.5 (20.8-41.6)\n0.0\n0.0\n\n\nIncome Level\n\n\nLow\n60.8 (41.0-78.3)\n71.5 (50.7-87.2)\n71.1 (50.4-86.8)\n0.5\n0.7\n\n\nMid\n15.3 (4.5-34.2)\n17.6 (5.9-36.6)\n14.1 (5.0-29.2)\n3.5\n19.8\n\n\nHigh\n3.3 (0.6-10.0)\n3.3 (0.6-10.0)\n3.3 (0.6-10.0)\n0.0\n0.0\n\n\nRace/Ethnicity\n\n\nWhite\n21.9 (15.3-29.9)\n27.1 (19.2-36.1)\n26.9 (19.0-36.0)\n0.2\n0.7\n\n\nAsian/Other\n44.7 (NC)\n44.7 (NC)\n44.7 (NC)\n0.0\n0.0\n\n\nBlack\n49.7 (13.9-85.8)\n50.5 (14.2-86.4)\n40.3 (3.7-88.9)\n10.2\n20.1\n\n\nHispanic\n37.6 (NC)\n37.6 (NC)\n37.6 (NC)\n0.0\n0.0\n\n\n\nNotes: Financial toxicity defined as annual household medical expenditures exceeding 20% of post-subsistence income. ‘Universal SGLT2i’ models the counterfactual cost if all patients were prescribed SGLT2i therapy at full 365-day adherence. ‘Post-IRA’ applies the $2,000 annual pharmacy cap to the Medicare Part D portion of these costs. Confidence Intervals calculated using Korn-Graubard (Beta) method. ‘NC’ indicates variance could not be calculated due to insufficient degrees of freedom.\n\n\n\n\n\n\n\n\n\n\n\n\nTable 3. Efficiency of the Policy Intervention: Number Needed to Harm/Treat (NNH/NNT) and Projected Annual Lives Protected.\n\n\n\n\n\n\n\n\n\n\nNumber Needed to Harm (Universal SGLT2i)\nNumber Needed to Treat (IRA Impact)\nLives Protected (Annual Estimate)\n\n\n\n\nOverall\n\n\nOverall\n23\n78\n13,943\n\n\nAge Group\n\n\n&lt;65\n6\nNegl.\n0\n\n\n65-74\n21\n180\n1,693\n\n\n75+\n34\n57\n12,250\n\n\nSex\n\n\nMale\n15\n36\n13,943\n\n\nFemale\n47\nNegl.\n0\n\n\nIncome Level\n\n\nLow\n9\nNegl.\n1,693\n\n\nMid\n44\n29\n12,250\n\n\nHigh\nNegl.\nNegl.\n0\n\n\nRace/Ethnicity\n\n\nWhite\n20\nNegl.\n1,693\n\n\nAsian/Other\nNegl.\nNegl.\n0\n\n\nBlack\n132\n10\n12,250\n\n\nHispanic\nNegl.\nNegl.\n0\n\n\n\nNotes: ‘Number Needed to Harm’ represents the number of patients treated with Universal SGLT2i to cause one additional case of financial toxicity. ‘Number Needed to Treat’ represents the number of patients who must benefit from the IRA cap to prevent one case of toxicity. ‘Lives Protected’ is the product of the Absolute Risk Reduction and the weighted population size. ‘Negl.’ indicates negligible risk difference (&lt;0.5%).\n\n\n\n\n\n\n\n\n\n\n\n\nFigure 1. The Impact of Universal SGLT2i Adherence and Provisions of the Inflation Reduction Act on Financial Toxicity Among Medicare Beneficiaries.\n\n\n\n\n\n\n\n\n\n\nFigure 2. Reductions in Financial Toxicity by Demographic Subgroup Under the Inflation Reduction Act.\n\n\n\n\n\n\n\n\n\n\nFigure 3. Distribution of Insurance Coverage Across Demographic Subgroups Explaining Differential Policy Impact.\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 1. Annualized Median Out-of-Pocket Costs for SGLT2i by Insurance Type (2023 Inflation-Adjusted Dollars).\n\n\n\n\n\n\n\n\n\nInsurance Plan\nSGLT2i Cost\nTotal Annual Cost\n\n\n\n\nMedicare\n$532\n$532\n\n\nMedicaid/Dual\n$0\n$0\n\n\nCommercial\n$91\n$91\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 2. Projected Annual Out-of-Pocket Savings for Medicare Beneficiaries Stratified by Income Level.\n\n\n\n\n\n\n\n\n\nIncome Level\nPre-IRA OOP ($)\nPost-IRA OOP ($)\nNet Savings ($)\n% Benefiting\nSavings (Among Beneficiaries)\n\n\n\n\nOverall\n$3,789\n$3,504\n$285\n13.1\n$2,179\n\n\nLow\n$2,758\n$2,467\n$292\n12.2\n$2,391\n\n\nMid\n$4,489\n$4,210\n$278\n13.9\n$1,998\n\n\nHigh\n$4,122\n$3,837\n$284\n13.1\n$2,170\n\n\n\n\n\n\n\n\n\n\n\nSupplementary Table 3. Sensitivity Analysis: Projected Financial Toxicity in the Overall U.S. HF Population (Including Commercial and Medicaid). Note: Impact is diluted in this view as ~40% of the population (Commercial/Medicaid) is ineligible for the IRA cap.\n\n\n\n\n\n\n\n\n\n\nBaseline (95% CI)\nUniversal SGLT2i (95% CI)\nPost-IRA (95% CI)\nAbsolute Reduction (%)\nRelative Reduction (%)\n\n\n\n\nOverall Population\n\n\nAll Patients\n28.3 (22.8-34.2)\n30.8 (25.0-37.1)\n30.0 (24.3-36.3)\n0.8\n2.5\n\n\nAge Group\n\n\n&lt;65\n28.0 (18.3-39.6)\n30.0 (19.5-42.3)\n30.0 (19.5-42.3)\n0.0\n0.0\n\n\n65-74\n28.5 (16.4-43.3)\n31.8 (19.2-46.8)\n31.4 (18.8-46.5)\n0.4\n1.3\n\n\n75+\n28.3 (19.8-38.2)\n30.9 (21.9-41.0)\n29.4 (20.4-39.6)\n1.5\n5.0\n\n\nSex\n\n\nMale\n24.2 (16.0-34.1)\n28.3 (18.9-39.2)\n26.6 (17.4-37.6)\n1.7\n5.9\n\n\nFemale\n31.7 (24.0-40.2)\n32.9 (25.1-41.5)\n32.9 (25.1-41.5)\n0.0\n0.0\n\n\nIncome Level\n\n\nLow\n57.3 (46.2-67.8)\n62.2 (51.0-72.6)\n62.0 (50.9-72.3)\n0.2\n0.3\n\n\nMid\n10.6 (3.5-23.3)\n12.1 (4.4-25.0)\n9.8 (3.8-19.8)\n2.3\n18.7\n\n\nHigh\n2.6 (0.6-7.3)\n2.6 (0.6-7.3)\n2.6 (0.6-7.3)\n0.0\n0.0\n\n\nRace/Ethnicity\n\n\nWhite\n24.2 (18.1-31.1)\n27.6 (21.0-35.0)\n27.5 (20.9-34.9)\n0.1\n0.5\n\n\nAsian/Other\n33.3 (0.0-100.0)\n33.3 (0.0-100.0)\n33.3 (0.0-100.0)\n0.0\n0.0\n\n\nBlack\n40.5 (25.0-57.5)\n40.8 (25.2-57.9)\n36.9 (20.5-55.9)\n3.9\n9.7\n\n\nHispanic\n41.4 (1.8-94.1)\n41.4 (1.8-94.1)\n41.4 (1.8-94.1)\n0.0\n0.0\n\n\nInsurance Type\n\n\nCommercial\n7.0 (0.6-26.0)\n7.0 (0.6-26.0)\n7.0 (0.6-26.0)\n0.0\n0.0\n\n\nMedicaid/Dual\n38.2 (26.3-51.1)\n38.2 (26.3-51.1)\n38.2 (26.3-51.1)\n0.0\n0.0\n\n\nMedicare\n26.2 (19.7-33.6)\n30.5 (23.3-38.6)\n29.3 (21.9-37.5)\n1.3\n4.2\n\n\n\nConfidence Intervals calculated using Korn-Graubard method. ‘NC’ indicates variance could not be calculated due to insufficient degrees of freedom (single PSU)."
  }
]